BACK

CompuVax, Inc. and the University of Washington enter into an exclusive license agreement to develop RSV vaccines

04.01.15

CompuVax, Inc. and the University of Washington enter into an exclusive license agreement to develop RSV vaccines

Del Mar, April 1, 2015

CompuVax, Inc. and the University of Washington have entered into an exclusive license agreement for the development of vaccines against the respiratory syncytial virus.

The agreement covers know-how and patent applications on certain epitope scaffolds engineered by Bill Schief's laboratory at the University of Washington prior to 2014.

CompuVax, Inc. will be the exclusive licensee worldwide for these engineered antigens.